1. A preparation for immunotherapy based on bee venom, characterized in that said bee venom essentially does not contain mellitin. ! 2. The preparation according to claim 1, wherein said preparation is obtained by dialysis of the native bee venom using a membrane with a transmission limit of 10 kDa. ! 3. The drug according to claim 1 or 2, in which the primary amino groups of the protein parts of said mellitin-depleted bee venom are subjected to carbamylation or thiocarbamylation or the formation of guanidine type groups to produce monomeric allergoids. ! 4. The drug according to claim 3, in which these primary amino groups are terminal amino groups and / or ε-amino residues of lysine. ! 5. The drug according to claim 3, characterized in that all or part of the primary amino groups of the protein components of the specified mellitin-depleted bee venom have the following structure (I):! ! where X represents O, S or NR2, where R2 represents H, alkyl containing 1-6 carbon atoms, phenyl or CN, and R1 represents H, alkyl containing 1-8 carbon atoms, phenyl or arylalkyl containing up to 8 atoms carbon, or alkyl containing a heterocyclic ring. ! 6. The drug according to claim 5, where the specified drug is water soluble. ! 7. The drug according to claim 5, in which the average percentage of modified primary amino groups is more than 75%. ! 8. The drug according to claim 7, in which the average percentage of modified primary amino groups is approximately 90%. ! 9. The preparation according to claim 3, obtained by treating said mellitin-depleted bee venom with an alkaline cyanate, such as KCNO or NaCNO, or with organic isocyanates or isothiocyanates at a pH of 7 to 11.! 10. The drug1. Препарат для иммунотерапии на основе пчелиного яда, отличающийся тем, что указанный пчелиный яд, по существу, не содержит меллитина. !2. Препарат по п.1, где указанный препарат получают диализом нативного пчелиного яда, используя мембрану с границей пропускания 10 кДа. ! 3. Препарат по п.1 или
